A novel human glassy-cell carcinoma cell line producing IL-6 and IL-8 from uterine cervix

Oki, Akinori; Nishida, Masato; Tsunoda, Hajime; K, Kasahara; Saijo, Kaoru; Kubo, Takeshi; Ohno, Tadao

doi:10.1007/s11626-998-0005-1

Cited by 4 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased IL-8 expression is seen in Pneumocystis carinii infection of the lung and infectious/inflammatory diseases affecting the female genital tract such as malaria, human papillomavirus (HPV), and bacterial vaginosis (BV). 12,13,[20][21][22][23][24][25][26][27][28] All of these conditions have been shown to exacerbate sexual or mother to child (MTCT) HIV-1 transmission. 2,4,13,25,29 IL-8 is a chemokine that shares the receptors CXCR1 and CXCR2 with GRO-␣.…”

Section: Figmentioning

confidence: 99%

IL-8 Increases Transmission of HIV Type 1 in Cervical Explant Tissue

Narimatsu

Wolday²,

Patterson³

2005

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Interleukin-8 (IL-8) is the predominant cytokine expressed in the female genital tract of women with certain infectious/inflammatory conditions. IL-8 increased HIV-1 replication in T cells and to a greater extent in monocytes/macrophages in vitro. Physiological levels of IL-8 increased susceptibility to HIV-1 infection 5- to 8-fold in cervical explant tissues. Competitive inhibition of the IL-8 receptor CXCR2 with the small molecule inhibitor SB225002 resulted in a 45-70% decrease in cervical explant susceptibility to HIV-1 infection.

show abstract

Section: Figmentioning

confidence: 99%

IL-8 Increases Transmission of HIV Type 1 in Cervical Explant Tissue

Narimatsu

Wolday²,

Patterson³

2005

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

show abstract

“…Littman et al [5] reported poor results with either surgery and/or radiotherapy. Oki et al [14] reported that a cell line established from GCC showed a slow growth and doubling time, which might be one of the reasons for the radiation resistance. Deshpande et al [12] reported that patients with GCC treated with a combination of surgery, radiotherapy and chemotherapy showed a poor response.…”

Section: Discussionmentioning

confidence: 99%

A case of glassy cell carcinoma of the uterine cervix that responded to neoadjuvant chemotherapy with paclitaxel and carboplatin

Takekuma¹,

Hirashima²,

Takahashi³

et al. 2006

Anti-Cancer Drugs

View full text Add to dashboard Cite

Glassy cell carcinoma of the uterine cervix is a rare tumor, and has a poor prognosis because of its aggressive clinical behavior and resistance to radiotherapy and chemotherapy. We report a case of bulky glassy cell carcinoma of the uterine cervix that effectively responded to paclitaxel and carboplatin in a neoadjuvant setting. The patient was a 30-year-old woman who became aware of vaginal bleeding and was referred to our hospital because of a cancerous tumor of the uterine cervix. Physical examination showed the cervical tumor to be approximately 8 cm in diameter with no involvement of the parametrium or vagina. The biopsy results suggested a diagnosis of glassy cell carcinoma. The final diagnosis was glassy cell carcinoma of the uterine cervix, stage 1b2. Neoadjuvant chemotherapy with paclitaxel and carboplatin was administered for downstaging. The response rate was 67.9% (partial response) under magnetic resonance imaging, and elevated serum cancer-related antigen 125 (119 U/ml) and squamous cancer cell antigen (34 ng/ml) were reduced to 34 U/ml and 3.3 ng/ml, respectively. Following neoadjuvant chemotherapy, she underwent radical hysterectomy and adjuvant chemotherapy with the same regimen. The clinical course was very good. We speculate that glassy cell carcinoma is a sensitive tumor to paclitaxel and carboplatin. Further evaluation concerning diagnosis and treatment, however, is needed to improve the prognosis of patients with glassy cell carcinoma.

show abstract

A case of glassy cell carcinoma of the uterine cervix effectively responding to chemotherapy with paclitaxel and carboplatin

Hirashima¹,

Kobayashi²,

Nishiguchi³

et al. 2001

Anti-Cancer Drugs

View full text Add to dashboard Cite

Glassy cell carcinoma (GCC) of the uterine cervix is a highly malignant tumor and has a poor prognosis. As yet, no effective systemic chemotherapy to this tumor has been reported. Here we describe a case of recurrent GCC that responded to paclitaxel and carboplatin combination treatment. The patient, a 32-year-old woman, with clinical staging FIGO IB1 disease had a radical hysterectomy and postoperative radiotherapy. Three months after initial treatment, she had a relapse as peritoneal dissemination, which was confirmed in the second surgery (adnectomy) and which did not respond to platinum-based conventional chemotherapy (cisplatin, adriamycin, cyclophosphamide and carboplatin, etoposide). The recurrent peritoneal tumors responded well to paclitaxel and carboplatin combination treatment. An elevated serum concentration of carcinoembryonic antigen (672 ng/ml) was reduced to 14.4 ng/ml by six such courses. Peritoneal histopathology confirmed a complete response in the third surgery (ileostomy) for adhesive ileus by the radiotherapy. This is the first report of effective systemic chemotherapy with paclitaxel and carboplatin to recurrent GCC of the uterine cervix.

show abstract

A novel human glassy-cell carcinoma cell line producing IL-6 and IL-8 from uterine cervix

Cited by 4 publications

References 24 publications

IL-8 Increases Transmission of HIV Type 1 in Cervical Explant Tissue

IL-8 Increases Transmission of HIV Type 1 in Cervical Explant Tissue

A case of glassy cell carcinoma of the uterine cervix that responded to neoadjuvant chemotherapy with paclitaxel and carboplatin

A case of glassy cell carcinoma of the uterine cervix effectively responding to chemotherapy with paclitaxel and carboplatin

Contact Info

Product

Resources

About